Noted Gene Therapy Specialist, Dr. Roger Hajjar, Appointed to Atamyo Therapeutics Board of Directors

EVRY, France, July 24, 2023 (VSNewsNetwork.com) - Atamyo Therapeutics, a biotech firm specializing in the development of novel gene therapies for muscular dystrophies and cardiomyopathies, has announced the appointment of Dr. Roger J. Hajjar to its Board of Directors. Dr. Hajjar, currently serving as the Director of the Gene and Cell Therapy Institute at Mass General Brigham in Boston, is internationally recognized for his pioneering work in gene therapy, with his contributions widely utilized by investigators worldwide.

Stephane Degove, Atamyo’s Chief Executive Officer, discussed Dr. Hajjar's appointment, saying, "Roger's extensive experience in cell and gene therapy will be of significant value as we continue our work on gene therapies for Limb-Girdle Muscular Dystrophies and cardiomyopathies." Dr. Hajjar also shared his perspective on the appointment, saying, "I am eager to contribute to Atamyo’s mission to develop treatments for these devastating diseases."

For more detailed information on Atamyo Therapeutics and its ongoing initiatives, visit www.atamyo.com.

Source: Atamyo Therapeutics via Business Wire